TIMP2和IGFBP7的生物学功能及其在肾脏损伤过程中作用的研究进展

 急性肾损伤（acute kidney injury，AKI）是临床常见危重症，发生率高，死亡率高。AKI的早期诊断和治疗是降低死亡率和治疗成本的有效方法。目前临床上早期诊断AKI的生物标志物是尿液中金属蛋白酶组织抑制因子2（tissue inhibitors of metalloproteinase 2，TIMP2）和胰岛素样生长因子结合蛋白7（insulin-like growth factor binding protein 7，IGFBP7）浓度的乘积。TIMP2和IGFBP7的生物学功能，特别是在肾脏中的作用尚不清楚。本文首先分析二者所属家族的蛋白特征和生物学功能，再对二者在肾脏发育和AKI过程中的作用进行文献分析，从而为临床医师深入了解TIMP2和IGFBP7作为AKI生物标志物之外的作用和功能提供参考，并为其准确利用TIMP2和IGFBP7诊断和治疗AKI提供依据。

Research progress on the biological functions of TIMP2 and IGFBP7 and their roles in acute kidney injury

Acute kidney injury (AKI) is a common clinical critical complication with high incidence and mortality. Early diagnosis and treatment of AKI is an effective way to reduce mortality and treatment costs. At present, the biomarker for diagnosis of AKI is the product of the concentration of tissue inhibitors of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) in urine.However, the biological functions of TIMP2 and IGFBP7, especially in the kidney, remain unclear compared with other biomarkers of AKI.Therefore, we reviewed the protein characteristics and biological functions of the two families, as well as the role of the two proteins in kidney development and AKI progression, which can provide a theoretical reference for clinicians to understand TIMP2 and IGFBP7 in addition to their role as AKI biomarkers and a new perspective for more accurate and efficient use of TIMP2 and IGFBP7 in diagnosis and treatment of AKI.